Axsome receives FDA approval for Auvelity to treat Alzheimer’s agitation

Axsome Therapeutics has received the US Food and Drug Administration (FDA) approval for Auvelity (dextromethorphan HBr and ...
MedPage Today on MSN

FDA approves first non-antipsychotic drug for Alzheimer's agitation

Oral NMDA receptor antagonist gets an expanded indication ...

Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s ...

AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to ...
Clinical Trials Arena

Auvelity becomes first non-antipsychotic approved for Alzheimer’s agitation

Auvelity targets the NMDA and sigma-1 receptors, providing the first non-antipsychotic treatment option for Alzheimer’s patients with agitation.
PharmExec

FDA Approves Auvelity for Treatment of Agitation Associated with Dementia Due to Alzheimers

FDA cleared the first agent with an NMDA/sigma-1–based mechanism specifically for agitation in Alzheimer’s disease dementia, ...
EurekAlert!

Study: Researchers produce the first-ever image of an open NMDA receptor

Three distinct snapshots obtained with cryo-electron microscopy illustrate the arrangement of two of the four symmetrical subunits that make a functional NMDA receptor. During activation, as the ...